No Data
Express News | Corrected(Official)-Capricor Therapeutics Announces Pre-Bla Meeting With FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (Adds Dropped Words 'pre-Bla Meeting With FDA for Deramiocel')
CORRECTION: Capricor Therapeutics
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capric
Express News | Capricor Therapeutics Inc: FDA Scheduled Pre-Bla Meeting in Q3 for Deramiocel (Cap-1002)
Express News | Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $14
Oppenheimer analyst Leland Gershell maintains $Capricor Therapeutics(CAPR.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 34
Capricor Therapeutics Files for $150M Mixed Shelf